Confronto
Buserelin vs. FOXO4-DRI
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
57982-77-1
2074706-72-8
Peso molecolare
1239.42 g/mol
3735 g/mol
Emivita
nessun dato
0.5 h
Sequenza
nessun dato
D-Retro-Inverso-Variante eines FOXO4-Peptid-Fragments (LTLRKEPASEIAQSILEAYSQNGWANRRSGGKR — D-Aminosäuren in umgekehrter Sequenz)Meccanismo d'azione
Buserelin
Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.
FOXO4-DRI
FOXO4-DRI is the D-retro-inverso variant of a peptide fragment of the FOXO4 transcription factor. In senescent cells, FOXO4 is bound to p53, which suppresses p53-mediated apoptosis — the cells survive in a secreting 'zombie-like' state (senescence-associated secretory phenotype, SASP). The DRI peptide disrupts this FOXO4-p53 binding, freeing p53, and the senescent cell initiates apoptosis. Healthy cells are largely unaffected because p53 is not held back by FOXO4 in them. This selectivity was the central finding of the original 2017 publication.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Modello animale
Studi
0
3
di cui sull'uomo
0
0
Effetti registrati
2
3
Contraddizioni aperte
0
1
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Buserelin and FOXO4-DRI?
- Buserelin is classified as "Ricerca (altro)", while FOXO4-DRI is classified as "Ricerca (altro)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. FOXO4-DRI: Synthetic peptide with D-Retro-Inverso structure (all amino acids as D-form, sequence reversed), developed in 2017 as an experimental senolytic candidate. Goal: selective apoptosis of senescent cells via disruption of the FOXO4-p53 interaction. So far evaluated exclusively preclinically. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Buserelin or FOXO4-DRI?
- The highest available evidence level is "RCT sull'uomo" for Buserelin and "Modello animale" for FOXO4-DRI. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Buserelin and FOXO4-DRI in Germany and the United States?
- Germania: Buserelin — Su prescrizione, FOXO4-DRI — Solo ricerca. Stati Uniti: Buserelin — Non approvato, FOXO4-DRI — Solo ricerca. These are factual summaries with source and review date on the individual pages.